 |
This Web site is a component of the SAMHSA Health Information Network. |
|
Section III: Population Dynamics
Table 3. The increase in stimulant prevalence from four U.S. and one Canadian
population-based studies
| Increase1 |
Prevalence Change2
|
Period of Change3 |
Youth Age (years) |
Author |
| 4.0-fold |
0.52 → 2.4 survey |
1987-1996 |
≤18 |
Olfson et al. 2002 |
| 3.4-fold |
1.2 → 4.1 survey |
1987-1996 |
6-14 |
Olfson et al. 2002 |
| 2.2-fold |
4.4 → 9.5 Medicaid |
1992-1998 |
6-14 |
Rushton and Whitmire 2001 |
| 3.7-fold |
1.0 → 3.7 Medicaid |
1987-1996 |
<20 |
Zito et al. 2003 |
| 7.0-fold |
0.4 → 2.5 HMO |
| 4.0-fold |
1.7 → 6.8 Medicaid |
1987-1996 |
5-14 |
Zito et al. 2003 |
| 5.9-fold |
0.7 → 4.1 HMO |
| 1.3-fold |
2.3 → 3.0 IPA |
1995-1999 |
<20 |
Shatin and Drinkard 2002 |
| 5.8-fold |
0.2 → 4.1 total province |
19901996 |
<20 |
Miller et al. 2001 |
1 Fold-increase across the time interval measured.
2 Prevalence estimates were defined as the proportion of youths
with one or more prescription records for a stimulant per 100 enrolled youths
from start year to end year. Separate estimates for population-based national
survey, Medicaid, HMO, and IPA enrollees and Canadian provincial residents.
3 Start and end years assessed during the period of change. |
Back to Mental Health 2002
|
|
